Carlyle Secured Lending (CGBD) Q1 2026 Transcript

Carlyle Secured Lending reported Q1 net investment income of $0.36 per share on $64 million of total investment income, while NAV fell to $15.89 from $16.26 and aggregate net loss was $29 million, or $0.42 per share. Offset to the softer earnings profile, the company funded $217 million of investments, widened new loan spreads by nearly 50 bps, repurchased $19 million of stock at a 26% discount to NAV, and reset the base dividend to $0.35 per share for 2026. Management expects earnings to trough in Q2 before recovering as MMCF and the new SCP joint venture ramp.

Analysis

The setup is less about near-term earnings power and more about asset mix transition. Lower run-rate NII is being masked by buybacks and spillover, but the real second-order effect is that management is intentionally swapping away from legacy core-portfolio economics toward fee-free JV exposure with better return on equity. That should support a higher forward multiple if execution holds, because earnings visibility improves as the ramp shifts from balance-sheet capital intensity to third-party funded assets.

The market is likely underappreciating how much the widened spreads and looser supply-demand balance improve underwriting optionality for the next 2-3 quarters. If direct lenders keep re-pricing risk upward while private equity exit activity stays muted, CGBD can originate at better coupons and stronger docs while also selling older vintages into MMCF—effectively arbitraging vintage spread gaps. The key risk is that lower portfolio yields and shrinking average assets offset that benefit before the JV contribution becomes material, keeping the stock in a “show me” range through mid-2026.

From a credit lens, the headline concern is not current non-accruals; it is mark pressure in software and other duration-sensitive credits if spreads remain volatile. But the balance sheet is structured to absorb that, and the buyback at a deep discount creates a floor under NAV as long as liquidity stays intact. The contrarian view is that dividend reset is being read as a sign of stress when it is more likely a tactical de-risking to preserve capital for a more accretive deployment phase; if M&A re-accelerates into 2H26, the earnings inflection could be sharper than consensus expects.

Key Decisions for Investors

• Long CGBD for a 3-6 month rebound trade, sized as a tactical income-plus-NAV play; entry is attractive on weakness because the company is effectively monetizing discount-to-NAV via repurchases while the forward earnings trough appears near. Risk/reward: ~10-15% upside to rerating if JV ramp and credit marks stabilize, with downside buffered by buyback and spillover but capped if spreads widen again.
• Pair trade: long CGBD / short a higher-beta BDC with less buyback support and more floating-rate duration sensitivity over the next 1-2 quarters. The thesis is that CGBD's JV monetization and capital return program should hold up better than peers with weaker liquidity and less visible fee-free earnings contribution.
• Consider selling near-dated covered calls on CGBD against a core long position into the next earnings window. The stock may remain range-bound until investors see JV earnings contribution; call overwriting monetizes that time decay while retaining dividend carry.
• If you want convexity, buy 6-9 month CGBD calls rather than common stock. The catalyst is a 2H26 earnings inflection from JV ramp plus improved origination economics, and options isolate upside if the market re-rates the forward dividend stream faster than expected.
• Avoid chasing the stock after any rally tied only to dividend yield; wait for confirmation that core investment income has stabilized or that JV distributions are visibly ramping. Without that, the name can de-rate again on another quarter of yield compression.